On Oct. 8, 2020, Johnson & Johnson announced the European Commission, acting on behalf of the European Union (EU) Member States, had approved an Advance Purchase Agreement in which the Janssen Pharmaceutical will supply 200 million doses of its COVID-19 vaccine candidate to EU Member States following approval or authorization from regulators. The EU Member States also have the option to secure up to 200 million additional doses.